Equities analysts forecast that ARMO BioSciences (NASDAQ:ARMO) will report earnings per share (EPS) of ($0.45) for the current fiscal quarter, Zacks Investment Research reports. Zero analysts have provided estimates for ARMO BioSciences’ earnings. The lowest EPS estimate is ($0.78) and the highest is ($0.12). The company is expected to report its next quarterly earnings report on Monday, January 1st.
On average, analysts expect that ARMO BioSciences will report full-year earnings of ($2.68) per share for the current year, with EPS estimates ranging from ($5.14) to ($0.49). For the next year, analysts anticipate that the business will report earnings of ($2.27) per share, with EPS estimates ranging from ($2.83) to ($1.56). Zacks Investment Research’s earnings per share averages are a mean average based on a survey of research firms that follow ARMO BioSciences.
ARMO has been the topic of a number of research analyst reports. Robert W. Baird assumed coverage on ARMO BioSciences in a research note on Tuesday, February 20th. They issued an “outperform” rating and a $67.00 target price on the stock. Leerink Swann upgraded shares of ARMO BioSciences from a “market perform” rating to an “outperform” rating and set a $50.00 price target for the company in a research report on Tuesday, March 27th. BMO Capital Markets assumed coverage on shares of ARMO BioSciences in a research report on Tuesday, February 20th. They set an “outperform” rating and a $75.00 price target for the company. Finally, Jefferies Group assumed coverage on shares of ARMO BioSciences in a research report on Tuesday, February 20th. They set a “buy” rating and a $61.00 price target for the company.
ARMO traded down $0.69 during trading on Wednesday, reaching $36.72. The stock had a trading volume of 65,792 shares, compared to its average volume of 240,376. ARMO BioSciences has a one year low of $27.00 and a one year high of $57.19.
ARMO BioSciences Company Profile
ARMO Biosciences, Inc is a United States-based clinical-stage biopharmaceutical company. The Company focuses on developing immunotherapies for the treatment of cancer, cardiovascular disease, fibrosis and inflammation. The Company’s platform molecule AM0010 is a pegylated form of recombinant human IL-10, which has immune stimulating effects that induce the activation, proliferation and survival of intratumoral, tumor-reactive, cytotoxic CD8+ T cells in cancer patients.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for ARMO BioSciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ARMO BioSciences and related companies with MarketBeat.com's FREE daily email newsletter.